| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] |
| Indication |
For the treatment of chronic stable angina (classic effort-associated angina). |
| Pharmacology |
Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride. |
| Toxicity |
There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. |
| Absorption |
Rapidly and completely absorbed after oral administration. |
| Half Life |
24-50 hours |
| Protein Binding |
99% |
| External Links |
|